- Home
- NXTC vs AMZE Comparison
NXTC vs AMZE Comparison
Compare NXTC & AMZE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NXTC
- AMZE
- Stock Information
- Founded
- NXTC 2015
- AMZE 2019
- Country
- NXTC United States
- AMZE United States
- Employees
- NXTC N/A
- AMZE N/A
- Industry
- NXTC Biotechnology: Pharmaceutical Preparations
- AMZE Beverages (Production/Distribution)
- Sector
- NXTC Health Care
- AMZE Consumer Staples
- Exchange
- NXTC Nasdaq
- AMZE Nasdaq
- Market Cap
- NXTC 9.3M
- AMZE 8.0M
- IPO Year
- NXTC 2019
- AMZE 2021
- Fundamental
- Price
- NXTC $0.41
- AMZE $0.43
- Analyst Decision
- NXTC Strong Buy
- AMZE
- Analyst Count
- NXTC 2
- AMZE 0
- Target Price
- NXTC $3.50
- AMZE N/A
- AVG Volume (30 Days)
- NXTC 178.3K
- AMZE 78.9K
- Earning Date
- NXTC 05-01-2025
- AMZE 05-27-2025
- Dividend Yield
- NXTC N/A
- AMZE N/A
- EPS Growth
- NXTC N/A
- AMZE N/A
- EPS
- NXTC N/A
- AMZE N/A
- Revenue
- NXTC N/A
- AMZE $299,065.00
- Revenue This Year
- NXTC N/A
- AMZE N/A
- Revenue Next Year
- NXTC N/A
- AMZE N/A
- P/E Ratio
- NXTC N/A
- AMZE N/A
- Revenue Growth
- NXTC N/A
- AMZE N/A
- 52 Week Low
- NXTC $0.22
- AMZE $0.34
- 52 Week High
- NXTC $1.82
- AMZE $0.62
- Technical
- Relative Strength Index (RSI)
- NXTC 45.41
- AMZE N/A
- Support Level
- NXTC $0.34
- AMZE N/A
- Resistance Level
- NXTC $0.47
- AMZE N/A
- Average True Range (ATR)
- NXTC 0.06
- AMZE 0.00
- MACD
- NXTC 0.01
- AMZE 0.00
- Stochastic Oscillator
- NXTC 39.66
- AMZE 0.00
About NXTC NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.
About AMZE Amaze Holdings Inc. Common Stock
Amaze Holdings Inc provides a platform with a suite of solutions for easy product design and creation, commerce design applications, social commerce integrations, and services that enable creators to unlock their full creative and financial potential.